<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-058223</identifier>
<setSpec>1130-0108</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Effect of the rectal administration of indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes</dc:title>
<dc:description xml:lang="en">Background: hyperamylasemia and acute pancreatitis represent        the most frequent major complication after endoscopic retrograde        cholangiopancreatography (ERCP), developing in 1-30% of cases.        Objective: to determine the incidence of hyperamylasemia        and acute pancreatitis after ERCP, and to assess the utility of rectal        indomethacin to prevent these events.        Material and methods: a randomized clinical trial. During a        12-month period 150 patients were included. They were divided        up into a study group (n = 75), where 100 mg of rectal indomethacin        were administered 2 hours prior to the procedure, and a        control group (n = 75), which received rectal glycerin. Two hours        after ERCP serum amylase levels were measured and classified as        follows: 0 = 600 IU/L. Clinical        pancreatitis episodes were quantified and classified according to        Ranson&#146;s criteria.        Results: gender distribution: 100 women and 50 men. Mean        age: 55.37 ± 18.0 for the study group, and 51.1 ± 17.0 for the        control group. A diagnosis of benign pathology was present in 56        (74.7%) cases in the study group, and 59 (78.7%) controls. After        ERCP 13 (17.3%) patients in the study group and 28 (37.3%) in        the control group developed hyperamylasemia (p  600 IU/L was found in 3 patients in the study        group, and in 10 in the control group (p = 0.001). Mild pancreatitis        was detected in 4 (5.3%) patients in the study group, and in        12 (16%) patients in the control group (p = 0.034). There were        no deaths or adverse drug reactions.        Conclusions: rectal indomethacin before ERCP decreases        the risk of hyperamylasemia and pancreatitis. Indomethacine is a        feasible, low-cost drug with minimal or nil side effects</dc:description>
<dc:creator>Dávalos Cobián, C</dc:creator>
<dc:creator>García Correa, J. E</dc:creator>
<dc:creator>Montaño Loza, A</dc:creator>
<dc:creator>González Ojeda, A</dc:creator>
<dc:creator>Fuentes Orozco, C</dc:creator>
<dc:creator>Rodríguez Lomelí, X</dc:creator>
<dc:creator>Medrano Muñoz, F</dc:creator>
<dc:creator>Cervantes Guevara, G</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: hiperamilasemia y pancreatitis aguda representan        las complicaciones mayores más frecuentes posteriores a        colangiopancreatografía retrógrada endoscópica (CPRE), apareciendo        en 1-30% de los casos.        Objetivo: determinar la incidencia de hiperamilasemia y pancreatitis        posterior a CPRE y evaluar la utilidad de indometacina        rectal para la prevención de estos.        Material y métodos: ensayo clínico controlado. Durante un periodo        de 12 meses se incluyeron 150 pacientes. Estos fueron divididos        en grupo de estudio (n = 75), a quienes se administró indometacina        rectal 100 mg 2 horas previas al procedimiento, y control (n =        75) que recibió glicerina. Dos horas posteriores a la CPRE se determinó        el nivel de amilasa sérica y se clasificaron en: 0 = 600 UI/l. Los episodios de pancreatitis clínica se        cuantificaron y clasificaron de acuerdo a los criterios de Ranson.        Resultados: distribución por género: 100 mujeres y 50 hombres.        Edad media: 55,37 ± 18,0 para el grupo de estudio y 51,1 ±        17,0 para el control. El diagnóstico de patología benigna se presentó        en 56 (74,7%) casos del grupo de estudio y 59 (78,7%) del control.        Posterior al procedimiento, 13 (17,3%) pacientes del grupo experimental        y 28 (37,3%) del control desarrollaron hiperamilasemia        (p  600 UI/l en 3 pacientes        del grupo de estudio y 10 del control (p = 0,001). Se detectó pancreatitis        leve en 5,3% de los pacientes del grupo de estudio y 16%        del control (p &lt; 0,05). No hubo mortalidad ni eventos adversos.        Conclusiones: indometacina rectal previo a CPRE disminuye        el riesgo de hiperamilasemia y pancreatitis. La indometacina es        accesible, de bajo costo con mínimos o nulos efectos secundarios</dc:description>
<dc:source>Rev Esp Enferm Dig;99(6): 330-336, jun. 2007. ilus, tab</dc:source>
<dc:identifier>ibc-058223</dc:identifier>
<dc:title xml:lang="es">Efecto de la administración de indometacina rectal sobre los niveles séricos de amilasa posteriores a colangiopancreatografía retrógrada endoscópica y su impacto en la aparición de episodios de pancreatitis secundaria</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d695^s22062</dc:subject>
<dc:subject>^d37290^s22080</dc:subject>
<dc:subject>^d10382^s22054</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d37290^s22036</dc:subject>
<dc:subject>^d24551</dc:subject>
<dc:subject>^d29357^s22020</dc:subject>
<dc:subject>^d32388</dc:subject>
<dc:subject>^d28146^s22079</dc:subject>
<dc:subject>^d10382^s22080</dc:subject>
<dc:type>article</dc:type>
<dc:date>200706</dc:date>
</metadata>
</record>
</ibecs-document>
